Clinical trial · no report yet · Phase 3
SUPRAME
SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma
- NCT06743126 ↗
- Recruiting
- Immatics US, Inc.
- Standard
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 5 | |
| Podcasts | 3 | |
| YouTube | 2 | |
| Bluesky threads | 1 |
The trial
ClinicalTrials.gov- Official title
- A Prospective, Multicenter, Open-label, Randomized, Actively Controlled, Parallel-group Phase 3 Clinical Trial to Evaluate Efficacy, Safety, and Tolerability of IMA203 Versus Investigator's Choice of Treatment in Patients With Previously Treated, Unresectable or Metastatic Cutaneous Melanoma (ACTengine® IMA203-301)
- Phase
- Phase 3
- Status
- Recruiting
- Conditions
- Melanoma, Cutaneous Malignant
- Interventions
- IMA203; nivolumab plus relatlimab; lifileucel; nivolumab; pembrolizumab; ipilimumab; Dacarbazine; temozolomide; paclitaxel; paclitaxel plus carboplatin; Albumin-Bound Paclitaxel
- Arms
- Experimental arm · Experimental
- Control arm- investigator's choice · Active comparator
- Enrollment
- 360 (estimated)
- Primary outcomes
- Progression-free survival assessed by BICR
- Sponsor
- Immatics US, Inc.
- Start
- Jan 14, 2025
- Primary completion
- Jan 2028 (estimated)
- Results posted
- No
- Registry record
- NCT06743126 · updated Aug 18, 2026